Literature DB >> 7773578

Sepsis and septic shock. II. Treatment.

J Mayer1, R Hajek, J Vorlicek, M Tomiska.   

Abstract

Mortality from septic shock is considerable despite the advantages of cardiovascular support and antibiotic therapy. This article reviews current therapy of septic shock including immunotherapy and further possibilities of septic shock treatment. The role of cytokines, their inhibitors and antibodies to endotoxin is mentioned. Although these treatments hold much promise for the future, careful evaluation of both the benefits and complications of therapy is needed before widespread clinical use can be recommended.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7773578     DOI: 10.1007/bf00365850

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  144 in total

Review 1.  Intravenous immunoglobulin in combination with other prophylactic and therapeutic measures.

Authors:  U E Nydegger
Journal:  Transfusion       Date:  1992-01       Impact factor: 3.157

2.  Vasopressin in septic shock--a useful or dangerous agent?

Authors:  H M Morrison; P Doepfner; G R Park
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

3.  Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions.

Authors:  R C Bone
Journal:  Ann Intern Med       Date:  1991-02-15       Impact factor: 25.391

4.  The role of cytokines in septic shock and speculations on future therapies.

Authors:  A S Dofferhoff
Journal:  Neth J Med       Date:  1991-08       Impact factor: 1.422

Review 5.  Pathogenetic mechanisms of septic shock.

Authors:  J E Parrillo
Journal:  N Engl J Med       Date:  1993-05-20       Impact factor: 91.245

Review 6.  Hematologic malignancies and other marrow failure states: progress in the management of complicating infections.

Authors:  A S Levine; S C Schimpff; R G Graw; R C Young
Journal:  Semin Hematol       Date:  1974-04       Impact factor: 3.851

Review 7.  Oxygen transport in septic shock.

Authors:  J Takala; E Ruokonen
Journal:  Schweiz Med Wochenschr       Date:  1992-05-16

8.  Assessment of splanchnic oxygenation by gastric tonometry in patients with acute circulatory failure.

Authors:  N Maynard; D Bihari; R Beale; M Smithies; G Baldock; R Mason; I McColl
Journal:  JAMA       Date:  1993-09-08       Impact factor: 56.272

9.  Supplemental immunoglobulin (ivIgG) treatment in 163 patients with sepsis and septic shock--an observational study as a prerequisite for placebo-controlled clinical trials.

Authors:  G Pilz; S Kääb; G Neeser; I Class; U Schweigart; A Brähler; O Bujdoso; R Neumann; K Werdan
Journal:  Infection       Date:  1991 Jul-Aug       Impact factor: 3.553

Review 10.  Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide.

Authors:  M P Fink
Journal:  Crit Care Med       Date:  1993-02       Impact factor: 7.598

View more
  1 in total

1.  The Effect of Mesenchymal Stromal Cells on the Mortality of Patients with Sepsis and Septic Shock: A Promising Therapy.

Authors:  Emine Alp; Zeynep Burcin Gonen; Kursat Gundogan; Aliye Esmaoglu; Leylagul Kaynar; Aysun Cetin; Musa Karakukcu; Mustafa Cetin; Gamze Kalin; Mehmet Doganay
Journal:  Emerg Med Int       Date:  2022-06-24       Impact factor: 1.621

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.